Trials / Not Yet Recruiting
Not Yet RecruitingNCT06093698
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
An Exploratory Study of A-337 in the Management of Malignant Solid Dose
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- ITabMed Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
Detailed description
Protocol Number: IM-2021A Study Stage: Phase I Study Number: 2-3 sites Subject Number: up to 94 patients with recurrent or metastatic solid tumors, for whom there are no available effective standard treatments or for whom standard treatments have proven ineffective or intolerable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Anti-EpCAM-CD3 Antibody Injection | Intravenous Infusion |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
- First posted
- 2023-10-23
- Last updated
- 2023-10-23
Source: ClinicalTrials.gov record NCT06093698. Inclusion in this directory is not an endorsement.